Browsing Harvard Medical School by Keyword "ALK-1"

Now showing items 1-1 of 1

    • Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma 

      Wang, Xiaoen; Solban, Nicolas; Khanna, Prateek; Callea, Marcella; Song, Jiaxi; Alsop, David C.; Pearsall, R. Scott; Atkins, Michael B.; Mier, James W.; Signoretti, Sabina; Alimzhanov, Marat; Kumar, Ravi; Bhasin, Manoj K.; Bhatt, Rupal S. (Impact Journals LLC, 2016)
      Treatment of metastatic renal cell carcinoma (mRCC) with agents that block signaling through vascular endothelial growth factor receptor 2 (VEGFR2) induces disease regression or stabilization in some patients; however, ...